Debrisoquine hydroxylation in Parkinson's disease.

Abstract

Debrisoquine (DBQ) metabolism was studied in 80 Parkinson's disease (PD) patients, 26 of whom had young onset Parkinson's disease (YOPD), and in 143 controls. There was no significant difference between the proportion of poor metabolisers of DBQ among YOPD patients compared either to other parkinsonians, or to controls. Nor was there a significant correlation between the age of disease onset and DBQ metabolic ratio (MR). The results do not support the suggestion that impairment of DBQ metabolism (and hence cytochrome P450) is a primary defect in YOPD. However, in comparison with controls, MR values were modestly but significantly higher in PD patients, even in those not treated with drugs known to affect DBQ metabolism.

• Authors: M J Steiger, P Lledo, N P Quinn, C D Marsden, P Turner, P G Jenner
• Journal: Acta neurologica Scandinavica (Acta Neurol Scand) Vol. 86 Issue 2 Pg. 159-64 (Aug 1992) ISSN: 0001-6314 [Print] Denmark
• PMID: 1414226 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 4-hydroxydebrisoquin
• Cytochrome P-450 Enzyme System
• Mixed Function Oxygenases
• Cytochrome P-450 CYP2D6
• Debrisoquin

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Cytochrome P-450 CYP2D6
• Cytochrome P-450 Enzyme System (physiology)
• Debrisoquin (analogs & derivatives, pharmacokinetics)
• Female
• Humans
• Male
• Microsomes, Liver (drug effects, enzymology)
• Middle Aged
• Mixed Function Oxygenases (physiology)
• Neurologic Examination
• Parkinson Disease (enzymology, etiology)